Immuneering plans Phase 2 trial of atebimetinib plus PD-1 blockade in lung cancer patients
IMRX•Immuneering said preclinical results showed atebimetinib can strengthen PD-1 checkpoint blockade in RAS-mutant tumor models, supporting a planned Phase 2 lung cancer study. The findings will be presented Nov. 6, 2026, at the SITC annual meeting.
1. Planned lung cancer study
Immuneering plans a Phase 2 study pairing atebimetinib with PD-1 blockade in lung cancer, supported by preclinical results in RAS-mutant tumor models. The company will present the findings at the SITC annual meeting on Nov. 6, 2026.
